CAU
VIR icon

Caxton Associates (UK)’s Vir Biotechnology VIR Stock Holding History

Caxton Associates (UK)’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Buy
+12,527
New +$99.8K ﹤0.01% 745

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Caxton Associates (UK)'s VIR Position: Q1 2026 in Review

Caxton Associates (UK) opened a new position in Vir Biotechnology (VIR) in Q1 2026: 12,527 shares worth $112K. The stake represents ﹤0.01% of the portfolio and ranks #745 among its holdings.

251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Caxton Associates (UK) held 12,527 shares of Vir Biotechnology worth $112K as of Q1 2026.
  • Vir Biotechnology was a new Caxton Associates (UK) position in Q1 2026.
  • Vir Biotechnology made up ﹤0.01% of Caxton Associates (UK)'s portfolio in Q1 2026, its #745 holding.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.